Medical Affairs

Innoviva Specialty Therapeutics has created this website as a tool for healthcare professionals in the United States. The information presented on this platform is solely for informational purposes and is not meant to advertise or endorse the use of any particular product.

Publications & Presentations

Information provided in these publications, posters and presentations is intended for scientific review by medical professionals. This information is not considered medical advice and is not intended to promote the sale of any drug product.

For more information on GIAPREZA, including important safety information, please visit www.GIAPREZA.com.

For more information on XERAVA, including important safety information, please visit www.XERAVA.com.

For more information on XACDURO, including important safety information, please visit www.XACDURO.com.

Filter by Product

Marketed

Investigational

No results

GIAPREZA®

Dysfunction of the renin-angiotensin-aldosterone system in human septic shock

Resource Type

N/A

Author Name

Schaich CL, Leisman DE, Goldberg MB, Filbin MR, Khanna AK, Chappell MC

Date Published

March 2024

GIAPREZA®

Renin Levels and Angiotensin II Responsiveness in Vasopressor-Dependent Hypotension

Resource Type

N/A

Author Name

See EJ, Chaba A, Spano S, Maeda A, Clapham C, Burrell LM, Liu J, Khasin M, Liskaser G, Eastwood G, Bellomo R

Date Published

March 2024

GIAPREZA®

Plasma renin as a novel prognostic biomarker of sepsis-associated acute respiratory distress syndrome

Resource Type

N/A

Author Name

Chakradhar A, Baron RM, Vera MP, Devarajan P, Chawla L, Hou PC

Date Published

March 2024

GIAPREZA®

Clinical Response to Third-Line Angiotensin-II vs Epinephrine in Septic Shock: A Propensity-Matched Cohort Study

Resource Type

N/A

Author Name

Blankenship CR, Betthauser KD, Hencken LN, Maamari JA, Goetz J, Giacomino BD, Gibson GA

Date Published

February 2024

GIAPREZA®

A Pilot Study of Renin-Guided Angiotensin-II Infusion to Reduce Kidney Stress After Cardiac Surgery

Resource Type

N/A

Author Name

Sadjadi M, von Groote T, Weiss R, Strauß C, Wempe C, Albert F, Langenkämper M, Landoni G, Bellomo R, Khanna AK, Coulson T, Meersch M, Zarbock A

Date Published

January 2024

GIAPREZA®

Angiotensin II

Resource Type

N/A

Author Name

Bellomo R, Zarbock A, Landoni G

Date Published

January 2024

GIAPREZA®

Angiotensin II treatment is associated with improved oxygenation in ARDS patients with refractory vasodilatory shock

Resource Type

N/A

Author Name

Leisman DE, Handisides DR, Chawla LS, Albertson TE, Busse LW, Boldt DW, Deane AM, Gong MN, Ham KR, Khanna AK, Ostermann M, McCurdy MT, Thompson BT, Tumlin JS, Adams CD, Hodges TN, Bellomo R

Date Published

December 2023

GIAPREZA®

Is It Time to Reconsider the Concept of “Salvage Therapy” in Refractory Shock?

Resource Type

N/A

Author Name

Wieruszewski PM, Sevransky JE, Roberts RJ

Date Published

December 2023

GIAPREZA®

Angiotensin II for the Treatment of Refractory Shock: A Matched Analysis

Resource Type

N/A

Author Name

Smith LM, Mentz GB, Engoren MC

Date Published

December 2023

GIAPREZA®

Angiotensin II in liver transplantation (AngLT-1): protocol of a randomised, double-blind, placebo-controlled trial

Resource Type

N/A

Author Name

Bokoch MP, Tran AT, Brinson EL, Marcus SG, Reddy M, Sun E, Roll GR, Pardo M, Fields S, Adelmann D, Kothari RP, Legrand M

Date Published

November 2023

GIAPREZA®

Renin as a Prognostic Marker in Intensive Care and Perioperative Settings: A Scoping Review

Resource Type

N/A

Author Name

Teixeira JP, Perez Ingles D, Barton JB, Dean JT, Garcia P, Kunkel SJ, Sarangarm P, Weiss NK, Schaich CL, Busse LW, Nielsen ND

Date Published

October 2023

GIAPREZA®

Renin as a Prognostic Marker in Intensive Care and Perioperative Settings: A Scoping Review

Resource Type

N/A

Author Name

Kotani Y, Belletti A, Maiucci G, Lodovici M, Fresilli S, Landoni G, Bellomo R, Zarbock A

Date Published

October 2023

GIAPREZA®

Trajectory of PaO2/FiO2 Ratio in Shock After Angiotensin II

Resource Type

N/A

Author Name

N/A

Date Published

May 2023

XACDURO®

Sulbactam-durlobactam: A Step Forward in Treating Carbapenem-Resistant Acinetobacter baumannii (CRAB) Infections

Resource Type

Publication

Author Name

Watkins

Date Published

May 2023

GIAPREZA®

A Pilot Study Of Angiotensin II As Primary Vasopressor In Critically Ill Adults With Vasodilatory Hypotension: The Aramis Study

Resource Type

N/A

Author Name

Emily J See, Caroline Clapham, Jasmine Liu, Monique Khasin

Date Published

May 2023

XERAVA®

In vitro activity of eravacycline and comparator agents against bacterial pathogens isolated from patients with cancer

Resource Type

Publication

Author Name

Rolston

Date Published

March 2023

GIAPREZA®

Angiotensin II for Vasodilatory Hypotension in Patients Requiring Mechanical Circulatory Support

Resource Type

N/A

Author Name

Wieruszewski PM, Seelhammer TG, Barreto EF, Busse LW, Chow JH, Davison DL, Gaglani B, Khanna AK, Ten Lohuis CC, Mara KC, Wittwer ED

Date Published

December 2022

XERAVA®

Clinical Outcomes of Eravacycline in Patients Treated Predominately for Carbapenem-Resistant Acinetobacter baumannii

Resource Type

Publication

Author Name

Alosaimy

Date Published

October 2022

GIAPREZA®

Myocardial effects of angiotensin II compared to norepinephrine in an animal model of septic shock

Resource Type

N/A

Author Name

Garcia B, Su F, Dewachter L, Favory R, Khaldi A, Moiroux-Sahraoui A, Annoni F, Vasques-Nóvoa F, Rocha-Oliveira E, Roncon-Albuquerque R Jr, Hubesch G, Njimi H, Vincent JL, Taccone FS, Creteur J, Herpain A

Date Published

September 2022

GIAPREZA®

A double-blind randomised feasibility trial of angiotensin-2 in cardiac surgery

Resource Type

Publication

Author Name

Coulson

Date Published

September 2022

GIAPREZA®

Angiotensin II enhances bacterial clearance via myeloid signaling in a murine sepsis model

Resource Type

Publication

Author Name

Leisman

Date Published

August 2022

GIAPREZA®

Effects of angiotensin II in the management of perioperative hypotension in kidney transplant recipients

Resource Type

Publication

Author Name

Andrews

Date Published

July 2022

GIAPREZA®

The Association Between Angiotensin II and Renin Kinetics in Patients After Cardiac Surgery

Resource Type

N/A

Author Name

Meersch M, Weiss R, Massoth C, Küllmar M, Saadat-Gilani K, Busen M, Chawla L, Landoni G, Bellomo R, Gerss J, Zarbock A

Date Published

May 2022

XERAVA®

Assessing the Real-world Clinical Outcomes of Patients Treated with Eravacycline for Complicated Intra-abdominal Infections

Resource Type

Publication

Author Name

Alosaimy

Date Published

April 2022

GIAPREZA®

The Role of Angiotensin II in Poisoning-Induced Shock-a Review

Resource Type

N/A

Author Name

Chen A, Wong A

Date Published

April 2022

XERAVA®

A retrospective, multicentre evaluation of eravacycline utilisation in community and academic hospitals

Resource Type

Publication

Author Name

Hobbs

Date Published

November 2021

GIAPREZA®

Why the renin-angiotensin-aldosterone system (RAAS) in critically ill patients can no longer be ignored

Resource Type

N/A

Author Name

Zarbock A, Chawla L, Bellomo R

Date Published

November 2021

XERAVA®

Evaluation of Predictors of Clinical Success in Patients Treated with Eravacycline for Various Infections

Resource Type

Publication

Author Name

Alosaimy

Date Published

October 2021

XERAVA®

In Vitro Activity of Eravacycline Against Clinically Significant Bacteria Isolated from Patients with Cancer

Resource Type

Publication

Author Name

Gerges

Date Published

October 2021

GIAPREZA®

Serum renin and major adverse kidney events in critically ill patients: a multicenter prospective study

Resource Type

Publication

Author Name

Flannery

Date Published

August 2021

XACDURO®

In Vitro Antibacterial Activity and In Vivo Efficacy of Sulbactam-Durlobactam against Pathogenic Burkholderia Species

Resource Type

Publication

Author Name

Papp-Wallace

Date Published

February 2021

GIAPREZA®

A Multicenter Observational Cohort Study of Angiotensin II in Shock

Resource Type

Publication

Author Name

Smith

Date Published

November 2020

XERAVA®

Tomefa E Asempa, Sergey Izmailyan, Kenneth Lawrence, David P Nicolau

Resource Type

Publication

Author Name

Alosaimy

Date Published

October 2020

XERAVA®

A Real-World Assessment of Clinical Outcomes and Safety of Eravacycline: A Novel Fluorocycline

Resource Type

Publication

Author Name

Hise

Date Published

October 2020

XERAVA®

In vitro activity of eravacycline against common ribotypes of Clostridioides difficile

Resource Type

Publication

Author Name

Bassères

Date Published

October 2020

XERAVA®

In vitro activity of eravacycline compared with tigecycline against carbapenem-resistant Enterobacteriaceae

Resource Type

Publication

Author Name

Clark

Date Published

September 2020

XERAVA®

Eravacycline, a novel tetracycline derivative, does not induce Clostridioides difficile infection in an in vitro human gut model

Resource Type

Publication

Author Name

Buckley

Date Published

September 2020

GIAPREZA®

Angiotensin II Infusion for Shock: A Multicenter Study of Postmarketing Use

Resource Type

Publication

Author Name

Wieruszewski

Date Published

August 2020

GIAPREZA®

Impaired angiotensin II type 1 receptor signaling contributes to sepsis-induced acute kidney injury

Resource Type

Publication

Author Name

Leisman

Date Published

August 2020

GIAPREZA®

Angiotensin II for Critically Ill Patients With Shock After Heart Transplant

Resource Type

Publication

Author Name

Cutler

Date Published

August 2020

XERAVA®

Antibiotic Susceptibility of NDM-Producing Enterobacterales Collected in the United States in 2017 and 2018

Resource Type

Publication

Author Name

Lutgring

Date Published

August 2020

XERAVA®

In Vitro Activities of Eravacycline and Other Antimicrobial Agents against Human Mycoplasmas and Ureaplasmas

Resource Type

Publication

Author Name

Waites

Date Published

July 2020

GIAPREZA®

Renin and Survival in Patients Given Angiotensin II for Catecholamine-Resistant Vasodilatory Shock

Resource Type

Publication

Author Name

Bellomo

Date Published

July 2020

GIAPREZA®

Use of Angiotensin II in Severe Vasoplegia After Left Pneumonectomy Requiring Cardiopulmonary Bypass: A Renin Response Analysis

Resource Type

Publication

Author Name

Trethowan

Date Published

July 2020

XACDURO®

In vitro activity of sulbactam/durlobactam against global isolates of carbapenem-resistant Acinetobacter baumannii

Resource Type

Publication

Author Name

Seifert

Date Published

June 2020

XERAVA®

Real-world utilization of eravacycline in the outpatient setting

Resource Type

Publication

Author Name

Hwang

Date Published

May 2020

XACDURO®

In vitro activity of sulbactam/durlobactam against clinical isolates of Acinetobacter baumannii collected in China

Resource Type

Publication

Author Name

Yang

Date Published

April 2020

GIAPREZA®

COVID-19 and the RAAS—a potential role for angiotensin II?

Resource Type

Publication

Author Name

Busse

Date Published

April 2020

XERAVA®

Early Experience With Eravacycline for Complicated Infections

Resource Type

Publication

Author Name

Alosaimy

Date Published

March 2020

GIAPREZA®

Angiotensin II for the treatment of distributive shock in the intensive care unit: A US cost-effectiveness analysis

Resource Type

Publication

Author Name

Busse

Date Published

March 2020

XERAVA®

In Vitro Activity of Eravacycline against Gram-Positive Bacteria Isolated in Clinical Laboratories Worldwide from 2013 to 2017

Resource Type

Publication

Author Name

Morrissey

Date Published

February 2020

GIAPREZA®

Angiotensin I and angiotensin II concentrations and their ratio in catecholamine-resistant vasodilatory shock

Resource Type

Publication

Author Name

Bellomo

Date Published

February 2020

XERAVA®

Real-World Use of Eravacycline: A Case Series

Resource Type

Publication

Author Name

Lunsted

Date Published

December 2019

XERAVA®

Eravacycline for the treatment of complicated intra-abdominal infections

Resource Type

Publication

Author Name

Montravers

Date Published

October 2019

XERAVA®

Activity of Eravacycline Against Contemporary Gram-negative Clinical Isolates from New York City Hospitals

Resource Type

Publication

Author Name

Khan

Date Published

October 2019

XERAVA®

Comparative evaluation of ETEST® ERV* bioMérieux with the CLSI broth microdilution method for Eravacycline MIC determination

Resource Type

Publication

Author Name

SAUVONNET

Date Published

October 2019

XERAVA®

Novel Therapeutic Options for the Treatment of Multi-Drug Resistant Achromobacter Respiratory Infections

Resource Type

Publication

Author Name

Canonica

Date Published

October 2019

XERAVA®

Multicenter Evaluation of Eravacycline MIC Results for Enterobacteriaceae Using MicroScan Dried Gram Negative MIC Panels

Resource Type

Publication

Author Name

Traczewski

Date Published

October 2019

XERAVA®

Eravacycline: a new treatment option for complicated intra-abdominal infections in the age of multidrug resistance

Resource Type

Publication

Author Name

Solomkin

Date Published

October 2019

XERAVA®

Assessment of the Physical Compatibility of Eravacycline and Common Parenteral Drugs During Simulated Y-site Administration

Resource Type

Publication

Author Name

Avery

Date Published

October 2019

Zoliflodacin

Determination of MIC Quality Control Ranges for the Novel Gyrase Inhibitor Zoliflodacin

Resource Type

Publication

Author Name

Miller

Date Published

August 2019

XERAVA®

Comparative evaluation of Eravacycline MIC determination with the new ETEST® ERV* and CLSI broth microdilution method

Resource Type

Publication

Author Name

PILLON

Date Published

June 2019

GIAPREZA®

Sensitivity to angiotensin II dose in patients with vasodilatory shock: a prespecified analysis of the ATHOS-3 trial

Resource Type

Publication

Author Name

Ham

Date Published

June 2019

XERAVA®

Multi-Site Evaluation of Eravacycline MIC Test Strip (MTS) Compared To Broth Microdilution MICs

Resource Type

Publication

Author Name

OLESKY

Date Published

May 2019

XERAVA®

Multicenter Evaluation of Eravacycline MIC Results for E. coli Using MicroScan Dried Gram Negative MIC Panels

Resource Type

Publication

Author Name

Garner

Date Published

April 2019

XERAVA®

Eravacycline: A Review in Complicated Intra-Abdominal Infections

Resource Type

Publication

Author Name

Scott

Date Published

February 2019

Zoliflodacin

Single-Dose Pharmacokinetics, Excretion, and Metabolism of Zoliflodacin, a Novel Spiropyrimidinetrione Antibiotic, in Healthy Volunteers

Resource Type

Publication

Author Name

O’Donnell

Date Published

December 2018

Zoliflodacin

Single-Dose Zoliflodacin (ETX0914) for Treatment of Urogenital Gonorrhea

Resource Type

Publication

Author Name

Taylor

Date Published

November 2018

XERAVA®

In vitro susceptibility of β-lactamase-producing carbapenem-resistant Enterobacteriaceae (CRE) to eravacycline

Resource Type

Publication

Author Name

Zhang

Date Published

June 2018

XERAVA®

Pharmacokinetics and Comprehensive Analysis of the Tissue Distribution of Eravacycline in Rabbits

Resource Type

Publication

Author Name

Petraitis

Date Published

June 2018

GIAPREZA®

Outcomes in Patients with Vasodilatory Shock and Renal Replacement Therapy Treated with Intravenous Angiotensin II

Resource Type

Publication

Author Name

Tumlin

Date Published

June 2018

XERAVA®

Evaluation of the In Vitro Activity of Eravacycline against a Broad Spectrum of Recent Clinical Anaerobic Isolates

Resource Type

Publication

Author Name

Snydman

Date Published

May 2018

XERAVA®

In-vitro activity of the novel fluorocycline eravacycline against carbapenem non-susceptible Acinetobacter baumannii

Resource Type

Publication

Author Name

Seifert

Date Published

January 2018

XACDURO®

Acinetobacter baumannii OmpA Is a Selective Antibiotic Permeant Porin

Resource Type

Publication

Author Name

Iyer

Date Published

December 2017

XACDURO®

Kinetics of Sulbactam Hydrolysis by β-Lactamases, and Kinetics of β-Lactamase Inhibition by Sulbactam

Resource Type

Publication

Author Name

Shapiro

Date Published

November 2017

XERAVA®

In Vitro Activity of Eravacycline and comparator antimicrobials against 143 recent strains of Bacteroides species

Resource Type

Publication

Author Name

Citron,

Date Published

October 2017

XERAVA®

Impact of Meal Timing on Eravacycline Exposure During the Oral Portion of an IV to Oral Transition Dosing Regimen

Resource Type

Publication

Author Name

Horn

Date Published

October 2017

XACDURO®

Reversibility of Covalent, Broad-Spectrum Serine β-Lactamase Inhibition by the Diazabicyclooctenone ETX2514

Resource Type

Publication

Author Name

Shapiro

Date Published

August 2017

GIAPREZA®

Angiotensin II for the Treatment of Vasodilatory Shock

Resource Type

Publication

Author Name

Khanna

Date Published

August 2017

GIAPREZA®

Clinical Experience With IV Angiotensin II Administration: A Systematic Review of Safety

Resource Type

Publication

Author Name

Busse

Date Published

August 2017

XERAVA®

In Vivo Pharmacodynamic Target Assessment of Eravacycline against Escherichia coli in a Murine Thigh Infection Model

Resource Type

Publication

Author Name

Zhao

Date Published

July 2017

XERAVA®

A Divergent Route to Eravacycline

Resource Type

Publication

Author Name

Zhang

Date Published

December 2016

Zoliflodacin

In vitro growth of multidrug-resistant Neisseria gonorrhoeae isolates is inhibited by ETX0914, a novel spiropyrimidinetrione

Resource Type

Publication

Author Name

Papp

Date Published

July 2016

XERAVA®

In Vitro Activity of Eravacycline against Carbapenem-Resistant Enterobacteriaceae and Acinetobacter baumannii

Resource Type

Publication

Author Name

Livermore

Date Published

June 2016

XERAVA®

Review of Eravacycline, a Novel Fluorocycline Antibacterial Agent

Resource Type

Publication

Author Name

Zhanel

Date Published

April 2016

Zoliflodacin

Effect of Susceptibility Testing Conditions on the In Vitro Antibacterial Activity of ETX0914

Resource Type

Publication

Author Name

Giacobbe

Date Published

March 2016

Zoliflodacin

Update on Treatment Options for Gonococcal Infections

Resource Type

Publication

Author Name

Lancaster

Date Published

September 2015

Zoliflodacin

In Vitro Antibacterial Activity of AZD0914 against Human Mycoplasmas and Ureaplasmas

Resource Type

Publication

Author Name

Waites

Date Published

May 2015

XACDURO®

Molecular Mechanisms of Sulbactam Antibacterial Activity and Resistance Determinants in Acinetobacter baumannii

Resource Type

Publication

Author Name

Penwell

Date Published

February 2015

Zoliflodacin

In Vitro Activity of AZD0914, a Novel DNA Gyrase Inhibitor, against Chlamydia trachomatis and Chlamydia pneumoniae

Resource Type

Publication

Author Name

Kohlhoff

Date Published

November 2014

GIAPREZA®

Intravenous angiotensin II for the treatment of high-output shock (ATHOS trial): a pilot study

Resource Type

Publication

Author Name

Chawla

Date Published

October 2014

Zoliflodacin

Novel DNA Gyrase Inhibiting Spiropyrimidinetriones with a Benzisoxazole Scaffold: SAR and in Vivo Characterization

Resource Type

Publication

Author Name

Basarab

Date Published

October 2014

XERAVA®

Antibacterial Activity of Eravacycline (TP-434), a Novel Fluorocycline, against Hospital and Community Pathogens

Resource Type

Publication

Author Name

Sutcliffe

Date Published

November 2013

XERAVA®

Process R&D of Eravacycline: The First Fully Synthetic Fluorocycline in Clinical Development

Resource Type

Publication

Author Name

Ronn

Date Published

April 2013

XERAVA®

Target- and Resistance-Based Mechanistic Studies with TP-434, a Novel Fluorocycline Antibiotic

Resource Type

Publication

Author Name

Grossman

Date Published

February 2012

Zoliflodacin

Inhibition of Neisseria gonorrhoeae Type II Topoisomerases by the Novel Spiropyrimidinetrione AZD0914

Resource Type

Publication

Author Name

Kern

Date Published

April 2024

Request Medical Information

To speak to a Innoviva Specialty Therapeutics Information Professional, please visit our Contact page.

Report a Product Complaint

To report a complaint about an Innoviva Specialty Therapeutic product, please visit our Product Complaint page.

Report an Adverse Event

To report an adverse event with an Innoviva Specialty Therapeutic product, please visit our Adverse Event page.